Skip to main navigation
MIRUM

Header Menu

  • Who We Are
    • About Mirum
    • Leadership
    • Board of Directors
  • Programs
    • Pipeline
    • Maralixibat
    • Volixibat
    • Publications & Presentations
  • Patients & Families
    • Clinical Trials
    • Expanded Access
    • Progressive Familial Intrahepatic Cholestasis (PFIC)
    • Alagille Syndrome (ALGS)
    • Biliary Atresia (BA)
    • Intrahepatic Cholestasis of Pregnancy (ICP)
    • Primary Sclerosing Cholangitis (PSC)
  • Investors & Media
    • News Releases
    • Events and Presentations
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Management
      • Committee Composition
    • Financials & Filings
      • SEC Filing
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
    • Shareholder Services
      • Investor FAQs
      • Email Alerts
      • Contact IR
  • Careers
  • Contact Us
  • Menu

Investor Relations

  • News Releases
  • Events and Presentations
  • Corporate Governance
    • Documents & Charters
    • Board of Directors
    • Management
    • Committee Composition
  • Financials & Filings
    • SEC Filings
    • Analyst Coverage
  • Stock Information
    • Stock Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
  • Shareholder Services
    • Investor FAQs
    • Contact IR
    • Email Alerts

Investor Tools

  • Print

    Print

  • RSS Feeds

    RSS Feeds

  • Email Alerts

    Email Alerts

  • Search

    Search

  • Contact IR

    Contact IR

  • Email Page

    Email Page

SEC Filings

SEC Filings

Filing date Form Description Filing Group Issuer View
Nov 20, 2018 D

Notice of Exempt Offering of Securities

Other
Mirum Pharmaceuticals, Inc.
0001759425-18-000001.pdf
0001759425-18-000001.rtf
View HTML
Apr 18, 2019 DRS

Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

Registration Statements
Mirum Pharmaceuticals, Inc.
0000950123-19-003463.pdf
0000950123-19-003463.rtf
0000950123-19-003463.xls
View HTML
May 24, 2019 DRS/A

mendment to a previously filed DRS

Registration Statements
Mirum Pharmaceuticals, Inc.
0000950123-19-005709.pdf
0000950123-19-005709.rtf
0000950123-19-005709.xls
View HTML
Jun 21, 2019 S-1

Registration statement for face-amount certificate companies

Registration Statements
Mirum Pharmaceuticals, Inc.
0001193125-19-178671.pdf
0001193125-19-178671.rtf
0001193125-19-178671.xls
View HTML
Jul 08, 2019 S-1/A

Amended Registration statement for face-amount certificate companies

Registration Statements
Mirum Pharmaceuticals, Inc.
0001193125-19-189959.pdf
0001193125-19-189959.rtf
0001193125-19-189959.xls
View HTML
Jul 12, 2019 S-1/A

Amended Registration statement for face-amount certificate companies

Registration Statements
Mirum Pharmaceuticals, Inc.
0001193125-19-193277.pdf
0001193125-19-193277.rtf
0001193125-19-193277.xls
View HTML
Jul 15, 2019 8-A12B

Registration of certain classes of securities 12(b) of the Securities Exchange Act

Registration Statements
Mirum Pharmaceuticals, Inc.
0001193125-19-194022.pdf
0001193125-19-194022.rtf
0001193125-19-194022.xls
View HTML
Jul 17, 2019 3

Initial filing by director officer or owner of more than ten percent.

3,4,5
Mirum Pharmaceuticals, Inc.
0001209191-19-042433.pdf
0001209191-19-042433.rtf
View HTML
Jul 17, 2019 3

Initial filing by director officer or owner of more than ten percent.

3,4,5
Mirum Pharmaceuticals, Inc.
0001209191-19-042448.pdf
0001209191-19-042448.rtf
View HTML
Jul 17, 2019 3

Initial filing by director officer or owner of more than ten percent.

3,4,5
Mirum Pharmaceuticals, Inc.
0001209191-19-042429.pdf
0001209191-19-042429.rtf
View HTML

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page Next ›
  • Last page Last »
Displaying 1 - 10 of 144 results

Data provided by Kaleidoscope.

Header Menu

  • Who We Are
  • About Mirum
  • Leadership
  • Board of Directors
  • Programs
  • Pipeline
  • Maralixibat
  • Volixibat
  • Publications & Presentations
  • Patients & Families
  • Clinical Trials
  • Expanded Access
  • Progressive Familial Intrahepatic Cholestasis (PFIC)
  • Alagille Syndrome (ALGS)
  • Biliary Atresia (BA)
  • Intrahepatic Cholestasis of Pregnancy (ICP)
  • Primary Sclerosing Cholangitis (PSC)
  • Investors & Media
  • News Releases
  • Events and Presentations
  • Corporate Governance
  • Financials & Filings
  • Stock Information
  • Shareholder Services
  • Careers
  • Contact Us
© 2021 – Mirum Pharmaceuticals, Inc.
Scroll to top
  • Facebook
  • Twitter
  • LinkedIn